How COVID-19 Vaccines Were Developed
Historical Development
Traditional vaccine development timelines span 10–15 years. COVID-19 vaccines were developed and authorized within 11 months of the virus's genetic sequence being published — a feat explained by several factors:
- Pre-existing research platform: mRNA vaccine technology had been in development for over a decade at Moderna and BioNTech, with earlier work targeting MERS-CoV providing a blueprint for spike protein targeting.
- Massive parallel investment: Operation Warp Speed (U.S.) and similar programs globally committed funding for manufacturing at-risk before trial completion, compressing timelines.
- Overlapping trial phases: Phases 1, 2, and 3 were conducted with significant overlap rather than sequentially.
- Emergency regulatory pathways: FDA Emergency Use Authorization (EUA) and WHO Emergency Use Listing (EUL) enabled rapid deployment while full approval processes continued.
- High enrollment rates: Over 40,000 participants in the Pfizer Phase 3 trial alone yielded statistically robust results quickly.[V1]
Pfizer-BioNTech (Comirnaty)
Technology: Lipid nanoparticle-encapsulated mRNA encoding the SARS-CoV-2 spike protein.
How it works: mRNA instructs your cells to produce the spike protein; your immune system learns to recognize and neutralize it. The mRNA degrades within days and does not enter the cell nucleus or interact with DNA.[V2]
Efficacy: Original trial: ~95% against symptomatic disease. Effectiveness against severe disease and hospitalization remained high through Omicron era with updated boosters.
Status: FDA full approval (adults and children); updated annually for current circulating strains.
Moderna (Spikevax)
Technology: Lipid nanoparticle-encapsulated mRNA; higher mRNA dose (100 mcg primary vs. 30 mcg for Pfizer).
How it works: Same mechanism as Pfizer-BioNTech. Some research suggests the higher dose may produce modestly higher antibody titers.
Efficacy: Original trial: ~94.1% against symptomatic disease.[V7]
Status: FDA full approval; updated bivalent and monovalent formulations released for each variant season.
Novavax (Nuvaxovid)
Technology: Recombinant spike protein nanoparticles adjuvanted with Matrix-M — a more traditional protein-subunit approach similar to hepatitis B and pertussis vaccines.
How it works: Directly presents spike protein antigen alongside Matrix-M adjuvant to stimulate a robust immune response — no mRNA involved.
Efficacy: Phase 3 trial: ~90.4% against symptomatic disease (against original strain).[V8]
Status: FDA authorized; preferred option for individuals who decline mRNA vaccines for personal reasons.
AstraZeneca / Oxford (Vaxzevria)
Technology: Replication-deficient chimpanzee adenovirus vector carrying spike protein gene.
How it works: The adenovirus vector delivers DNA instructions for spike protein to cells. Associated with rare Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT), leading to restrictions or withdrawal in many high-income countries. Widely used in low- and middle-income countries via COVAX.
Status: Withdrawn from many markets by 2024; manufacturer acknowledged rare VITT risk in 2024 court proceedings.[V3]
The 2026–2027 season: current formulation and who is advised to get it
COVID-19 vaccines are reformulated each year to track the evolving virus, much as seasonal flu shots are. For the 2026–2027 season beginning in fall 2026, the U.S. Food and Drug Administration advised manufacturers that the updated shot should be a monovalent JN.1-lineage XFG formulation. FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) made this recommendation at its May 28, 2026 meeting, after reviewing which SARS-CoV-2 variants were circulating and how well existing vaccines matched them.[V4]
The World Health Organization's advisory group (TAG-CO-VAC) reached a closely related conclusion in its May 16, 2026 statement, recommending a monovalent LP.8.1 antigen while noting that other JN.1-lineage options — including JN.1, KP.2, XFG and NB.1.8.1 — remain acceptable where they produce broad neutralizing responses. Both bodies are targeting descendants of the JN.1 Omicron lineage that has driven most transmission worldwide since 2024.[V5]
Who is advised to get it: U.S. eligibility narrowed during 2025. The FDA now frames approval of the updated COVID-19 vaccines around adults aged 65 and older and people aged 6 months and older who have an underlying condition that raises their risk of severe COVID-19. In September 2025 the CDC's Advisory Committee on Immunization Practices (ACIP) shifted to individual-based (shared clinical) decision-making — advising that people decide about vaccination together with a health-care provider rather than under a blanket universal recommendation. This guidance has changed more than once, so confirm the current CDC recommendation and weigh your own risk factors before the season.[V6]
References
- Polack FP, et al. "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine." NEJM, 2020. doi:10.1056/NEJMoa2034577
- Pardi N, et al. "mRNA vaccines — a new era in vaccinology." Nature Reviews Drug Discovery, 2018. doi:10.1038/nrd.2017.243
- AstraZeneca conceded in April 2024 UK High Court filings that Vaxzevria can in rare cases cause TTS (Thrombosis with Thrombocytopenia Syndrome). Multiple verified news reports, April–May 2024.
- U.S. Food and Drug Administration. "COVID-19 Vaccines (2026-2027 Formula) for Use in the United States Beginning in Fall 2026." Content current as of May 29, 2026. fda.gov
- World Health Organization. "Statement on the antigen composition of COVID-19 vaccines." May 16, 2026. who.int
- Advisory Committee on Immunization Practices (ACIP), CDC. September 2025 recommendation that COVID-19 vaccination for eligible groups proceed through individual-based / shared clinical decision-making. See CDC COVID-19 vaccination guidance: cdc.gov
- Baden LR, et al. "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine" (COVE trial). NEJM, 2021. doi:10.1056/NEJMoa2035389
- Dunkle LM, et al. "Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico" (PREVENT-19 trial). NEJM, 2022. doi:10.1056/NEJMoa2116185
